ORKA
Oruka Stock Jumps 12.7% on Positive Week 16 Psoriasis Trial Data for ORKA-001
The 61% PASI 100 response in the high-dose group matched results from the earlier EVERLAST-A trial, and the company plans Phase 3 trials in the first half of 2027.
FDA and trials news
CLYM
Climb Bio Stock Falls 13.5% on the Day It Reported Early Kidney Drug Data
The filing, accepted before the open Monday, reported initial Phase 2 results for budoprutug in primary membranous nephropathy, and no source ties the decline to a specific item in it.
AVBP
ArriVent Shares Fall 27% on Monday, the Day Early ARR-217 Trial Data Were Filed
Neither the filing nor the press release attached to it says why the stock dropped, though the company called the early response rates encouraging.